All News
Filter News
Found 771 articles
-
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
5/6/2019
The procedure of certification of quality and non-clinical data involves an assessment of the available data in view of future registration and the related European Scientific Data Requirements, not including any clinical data or benefit-risk assessment.
-
Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019
5/1/2019
Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019.
-
Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs™) in a Peer-reviewed Journal
4/18/2019
Data demonstrates tumor-clearing ability of Inovio's dBiTE
-
Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress
4/17/2019
The Vaccine Industry Excellence Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders.
-
Novartis will use a priority review voucher to expedite review of the treatment that could hit blockbuster status within two years of launching.
-
Rare but important gene target found in many tumor types, suggesting new therapy possible
4/15/2019
A consortium of researchers led by Georgetown Lombardi Comprehensive Cancer Center investigators have completed the largest analysis of a new gene fusion they believe is responsible for development of a wide spectrum of cancer types.
-
The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.
-
Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development
4/8/2019
The milestone achievement for this multi-indication trial is the third MEDI0457-related Phase 2 milestone from AstraZeneca; two previous milestone payments resulted from initiating Phase 2 combination trials targeting head and neck and cervical cancers. Financial arrangements were not disclosed.
-
Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study
4/3/2019
Clinical Data Presented at Annual Meeting of American Association for Cancer Research
-
Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR
4/2/2019
Data demonstrates tumor-clearing ability of Inovio's dBiTE technology in preclinical cancer model
-
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
4/1/2019
Inovio Pharmaceuticals, Inc. announced that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma has completed its enrollment three months ahead of schedule.
-
Inovio Pharmaceuticals to Present at H.C. Wainwright Global Life Sciences Conference in London, UK
3/27/2019
Inovio Pharmaceuticals, Inc. announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 4:10 p.m. local time.
-
Inovio Appoints Global Commercial Leader to its Board of Directors
3/25/2019
Inovio Pharmaceuticals, Inc. announced the appointment of Dr. Ann C. Miller to its Board of Directors.
-
Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases
3/21/2019
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses.
-
FDA Green-Lights Two Therapies, While Late-Stage Successes Set Stage for Potential Approvals
3/12/2019
The U.S. Food and Drug Administration has been busy approving new treatments for various diseases. Two days into the new week and the regulatory agency has green lit two therapeutics, while other companies are planning to file for potential approval. -
Inovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results
3/12/2019
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, reported financial results for the fourth quarter and year ended December 31, 2018.
-
The next couple of weeks look to be busy for the FDA, with a string of target action dates scheduled. This week marks three scheduled approvals, two for extra indications for already-approved biologics, and the third for a combination treatment for glaucoma. Here’s a look.
-
Inovio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 12, 2019
3/5/2019
Inovio Pharmaceuticals, Inc. announced that 2018 fourth quarter and full year financial results will be released after the market close on March 12, 2019.
-
Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer
3/4/2019
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the initiation and opening of sites to enroll the second portion of the company's Phase 3 program for VGX-3100, Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV)
-
Inovio Pharmaceuticals Completes Sale of Additional Convertible Senior Notes
3/1/2019
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the sale of additional 6.50% convertible senior notes due 2024 (the "notes"), bringing the total amount of notes sold to $78.5 million in aggregate principal amoun